Wednesday, April 12, 2006
Sign Company Now Targets Sores, Nicotine Replacement
Dotronix, Inc. Completes Asset Purchase Agreement
MINNEAPOLIS--(BUSINESS WIRE)--April 12, 2006--Dotronix, Inc. (OTCBB:DOTX) announced today that it has completed an Asset Purchase Agreement with Accelerated Drug Delivery, a Wisconsin based limited liability company (ADD). Under the agreement Dotronix acquired from ADD all of its rights to three Over-The-Counter consumer healthcare products. The intended use of one product is to reduce the duration and severity of Canker Sores and of another product is to reduce the duration and severity of Cold Sores. The third product is intended to be used as a Nicotine Replacement product to aid consumers in their fight to quit smoking. Dotronix is acquiring the products in exchange for 492,121 shares of common stock or 6.19% of its outstanding common stock.
In connection with the agreement, Russell Mitchell and James Higgins have joined the Board of Directors of DOTX. Current board members Craig Laughlin and L. Daniel Kuechenmeister remain as board members.
Russ Mitchell and James Higgins each have over 20 years of sales and marketing experience. Russ, as president of Mitchell Health Technologies, has been a pioneer in establishing the marketing value of clinical trials to demonstrate the efficacy of OTC products. In addition to developing a sales network that currently services over 48,000 retail locations nationwide. Mr. Mitchell is also experienced in the formulation and manufacturing of prescription drugs, OTC Drugs and nutritional supplements.
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the Company's current expectations and involve known and unknown risks, uncertainties, or other factors which may cause actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect unanticipated events or developments.
Contacts
Dotronix, Inc.
Craig Laughlin, 952-541-1155
Dotronix, Inc.
Craig Laughlin, 952-541-1155
[ Editor's comment: If you are interested, the company does have a web site at http://www.dotronix.com. (hris ]
¶ 5:24 PM
